EBMT 2019 | Molecular techniques for monitoring MRD in AML
Torsten Haferlach
Torsten Haferlach, MD Munich Leukemia Laboratory, Munich, Germany, evaluates the different methods currently being used to monitor measurable residual disease (MRD) in acute myeloid leukemia (AML) patients. This video was recorder at the European Society for Blood and Marrow Transplantation (EBMT) 2019 Annual Meeting, held in Frankfurt, Germany.
Related videos
3:36
Cost-effectiveness of CAR T-cell therapy
Carin Al Uyl-de Groot
1:54
Upcoming EBMT Annual Meeting: Prof. Nagler's ALL picks
Arnon Nagler
3:30
The importance of standardized data collection of CAR T-cells therapy
Marcelo Pasquini
3:01
Academic vs. commercial CAR T-cell products
Arnon Nagler
1:29
Translation from academia to industry: manufacturing of CAR T-cells
Bruce Levine
